Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
GoodRx Holdings, Inc. appointed Thomas Chan as Chief Accounting Officer and designated him as the company’s principal accounting officer, effective immediately. Chan has held increasing accounting and reporting roles at GoodRx since 2020 and previously worked in audit and assurance at Deloitte & Touche.
In connection with his promotion, Chan’s annual base salary was set at $310,000 with a target annual bonus of 40% of base salary. He will receive a restricted stock unit award valued at $131,250 and a performance-based restricted stock unit award valued at $43,750 under the 2020 Incentive Award Plan, with multi-year time- and performance-based vesting schedules tied to continued employment.
GoodRx Holdings, Inc. officer Christopher A. McGinnis exercised 36,987 restricted stock units into Class A common stock and received the same number of shares at no cash cost. Of these, 10,745 shares were withheld at $2.23 per share to cover tax obligations, leaving 152,563 Class A shares held directly. Following the transaction, 406,865 restricted stock units remained outstanding, which vest in 12 equal quarterly installments starting on April 15, 2026, subject to continued service.
GoodRx Holdings, Inc. director and officer Wendy Lynn Barnes exercised restricted stock units into Class A common stock and had shares withheld to cover taxes. She converted 277,288 restricted stock units into the same number of Class A shares at a conversion price of $0.00 per share. To satisfy tax obligations, 120,456 Class A shares were disposed of at $2.23 per share through tax-withholding transactions, which are not open-market sales. After these transactions, she directly owns 584,825 shares of Class A common stock.
GoodRx Holdings, Inc. reported governance changes following a director departure. On March 31, 2026, Ian T. Clark resigned from the Board of Directors and the Nominating & Governance Committee, stating his decision was not due to any disagreement with the company or its management.
To rebalance director classes, the Board accepted Wendy Barnes’s resignation as a Class I director and immediately re-elected her as a Class III director. Her Board service is considered uninterrupted, and the Board now has three directors in each of Classes I, II, and III.
GoodRx Holdings, Inc. announced that Chief Accounting Officer Romin Nabiey has submitted his resignation, effective April 3, 2026, to pursue other opportunities. He will remain with the company through June 8, 2026 to help transition his responsibilities. The company stated that his resignation is not due to any disagreement regarding its operations, policies, or practices, and expressed appreciation for his years of service.
GoodRx Holdings Inc filing an amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares (0%) of Common Stock as shown in the amendment dated 03/13/2026. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
GoodRx Holdings, Inc. has changed its independent auditor. The Audit and Risk Committee approved the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and dismissed PricewaterhouseCoopers LLP from this role.
PWC’s audit reports on the 2025 and 2024 consolidated financial statements contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements or reportable events with PwC through March 14, 2026, and states it did not consult KPMG on accounting or auditing matters before this appointment.
GoodRx Holdings, Inc. director Agnes Rey-Giraud exercised stock options to acquire 192,185 shares of Class A common stock at $0.47 per share. On the same date, she made bona fide gifts totaling 150,438 shares, including 75,219 shares transferred to a family trust for which she is the sole trustee and beneficiary. Following these transactions, she continues to hold a substantial direct position in GoodRx stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity transactions involving restricted stock units and Class A common stock. On March 8, 2026, restricted stock units were converted into a total of 10,201 and 2,233 shares of Class A common stock at a price of $0.00 per share through derivative exercises.
In connection with these conversions, Class A shares were also disposed of under transaction code F to cover tax obligations, with 4,201 shares and 920 shares withheld at a price of $2.28 per share as tax-withholding dispositions. After these transactions, Nabiey directly owned 183,061 shares of Class A common stock.
Footnotes explain that each restricted stock unit represents a contingent right to receive one share of Class A common stock. One award began vesting December 8, 2022 with quarterly installments over 15 quarters, and another will begin vesting June 8, 2024 on a similar quarterly schedule.
GoodRx Holdings, Inc. reported a new executive compensation decision. On March 3, 2026, the Board of Directors, following a recommendation from its Compensation Committee, approved a discretionary cash bonus of $72,918 to Chief Accounting Officer Romin Nabiey for his performance during 2025.